Psychedelic-assisted therapy is a structured form of mental health treatment that combines a psychedelic substance with guided psychotherapy sessions. Unlike taking a medication daily, this approach typically involves only one to three dosing sessions, each bookended by extensive talk therapy before and after. The goal is not the drug experience itself but the psychological breakthroughs it can facilitate when paired with professional support.
No psychedelic substance is currently FDA-approved for therapeutic use. However, the FDA has granted “breakthrough therapy” status to psilocybin (the active compound in magic mushrooms), MDMA (commonly associated with ecstasy), and LSD, signaling that each shows potential for significant improvement over existing treatments for conditions like depression and PTSD.
How the Three Phases Work
Psychedelic-assisted therapy follows a consistent structure across most clinical programs, broken into three distinct phases: preparation, the dosing session, and integration.
Preparation involves multiple therapy sessions before any substance is taken. During this phase, therapists build rapport, assess your mental health history, establish treatment goals, and help you develop a sense of what to expect during the psychedelic experience. This groundwork is considered essential. People with significant trauma histories, for example, are expected to have fundamental coping skills and a safety plan in place before proceeding.
The dosing session is the supervised experience itself. You take the substance in a controlled clinical setting, typically a comfortable room designed to feel safe rather than clinical. One or two trained therapists remain present throughout, which can last anywhere from four to eight hours depending on the substance. Their role is largely supportive: they guide you through difficult emotional material if it surfaces but generally let the experience unfold on its own.
Integration is where the lasting therapeutic work happens. Starting shortly after the dosing session and continuing over weeks, integration sessions give you and your therapist space to process what came up during the experience. There’s an accounting of emotions, imagery, and memories that surfaced, followed by interpretation of their significance. Therapists apply traditional psychotherapy techniques to help identify triggers, recognize links to unhelpful behavioral patterns, and develop strategies for managing those patterns going forward. The central goal is translating any insights or realizations into concrete, lasting changes in everyday life. Integration also addresses new psychosocial challenges that can arise after the experience, since the emotional material that surfaces can sometimes be destabilizing before it becomes constructive.
Which Substances Treat Which Conditions
The four substances most studied in clinical settings each have distinct effects on the brain and are being evaluated for different conditions.
- Psilocybin is the most broadly studied. It’s being evaluated for treatment-resistant depression, major depressive disorder, end-of-life anxiety in terminal illness, and substance use disorders including alcohol and tobacco dependence.
- MDMA works differently from classic psychedelics. It increases the release of mood-related brain chemicals and boosts oxytocin, which promotes feelings of trust and emotional closeness. This makes it uniquely suited for trauma-focused therapy, and most clinical research has targeted treatment-resistant PTSD.
- LSD is being studied for anxiety, depression, and substance use disorders, though its research is less advanced than psilocybin’s.
- Ketamine acts through a completely different brain mechanism and offers rapid relief from depressive symptoms, sometimes within hours. It’s already legally available through off-label prescribing in some clinical settings, making it the most accessible option right now, though its effects tend to be shorter-lived without repeated sessions.
What the Evidence Shows for Depression
The strongest clinical data so far centers on psilocybin for depression. A systematic review and meta-analysis published in The BMJ, pooling data from seven trials and 436 participants, found that psilocybin produced a statistically significant reduction in depression scores compared to placebo. The effect size was moderate to large.
The numbers on response and remission are striking. Participants who received psilocybin were roughly twice as likely to experience a meaningful treatment response (defined as a 50% decrease in symptom severity) compared to those given a placebo. For full remission, the odds were nearly three times greater with psilocybin. These results are particularly notable because many participants had already tried conventional antidepressants without success.
That said, these trials were relatively small, and the therapeutic context matters enormously. Psilocybin in these studies was always paired with professional psychotherapy, not taken in isolation. Researchers consistently emphasize that the combination of the substance and the structured therapy appears to be what drives outcomes, not the drug alone.
Where FDA Approval Stands
Despite promising trial results, the path to regulatory approval has been bumpy. In August 2024, the FDA declined to approve MDMA for PTSD, even though two phase 3 trials had produced positive findings. The agency asked the drug’s sponsor, Lykos Therapeutics, to conduct an additional phase 3 trial before reconsidering. Concerns centered on study design issues rather than a rejection of the therapy’s potential.
Psilocybin may be closer to the finish line. Some researchers estimate it could gain FDA approval within the next couple of years, which would make it the first psychedelic substance approved for psychiatric use in the United States. Until then, access outside of clinical trials remains limited, with the exception of ketamine, which doctors can already prescribe off-label, and a small number of state-level programs in Oregon and Colorado that have legalized supervised psilocybin services.
Who Should Not Receive This Treatment
Psychedelic-assisted therapy is not appropriate for everyone, and the exclusion criteria are strict. People with a personal or family history of schizophrenia, schizoaffective disorder, or bipolar I disorder face serious risks, including prolonged psychosis. The same applies to anyone who experiences psychotic symptoms during depressive episodes.
There are also significant medical exclusions. Psychedelics are contraindicated during pregnancy and for people with epilepsy or other seizure disorders, severe cardiovascular disease, uncontrolled blood pressure, heart failure, coronary artery disease, or a history of heart attack or stroke. Classic psychedelics also interact dangerously with common antidepressants, including SSRIs and MAO inhibitors, so candidates typically need to taper off these medications under medical supervision before treatment can begin.
Previous adverse reactions to psychedelics, such as prolonged psychosis or suicidal ideation, also rule someone out. And people with significant trauma who haven’t yet developed basic coping skills through conventional therapy are advised to complete that foundational work first, since psychedelics can surface overwhelming emotional material that requires a certain level of psychological stability to process safely.